Primary Progressive Multiple Sclerosis (PPMS) is a kind of MS that affects around 15% of all MS patients. PPMS, unlike other types of MS, is distinguished by a progressive worsening of symptoms over time, with no discernible intervals of relapse and remission. This makes it an especially difficult condition to treat, and there are currently no FDA-approved therapies for PPMS.
However, various off-label therapies are utilised to control PPMS symptoms. Corticosteroids, immunosuppressants, and disease-modifying treatments (DMTs) authorised for different types of MS are among them. Physical therapy and rehabilitation are frequently suggested to assist patients in maintaining their mobility and independence.
The Global Primary Progressive Multiple Sclerosis Treatment Market was valued at US$ 994.3 million in 2022 and is anticipated to reach US$ 3,012.8 million by the end of 2030 expected to register a CAGR of 14.9% from 2023 to 2030.
Several medications targeting PPMS are now under development, including ocrelizumab, Siponimod, and masitinib. The FDA authorised ocrelizumab for the treatment of PPMS in 2017, making it the first medicine specifically approved for this kind of MS. Siponimod and masitinib are currently in clinical studies, but first findings are favourable.
Despite the difficulties associated with treating PPMS, the market for PPMS medicines is projected to expand in the future years as more people are identified and new treatments are discovered. However, the high expense of these medicines may prevent some patients from receiving them, emphasising the need for ongoing research and development of more inexpensive alternatives.
PPMS is a very uncommon variant of MS that affects around 10-15% of all MS patients. It usually appears in people in their 40s or 50s and is more frequent in males than in women. PPMS is distinguished by a progressive worsening of symptoms over time, which might include muscular weakness, trouble walking, tiredness, and visual, speech, and cognition impairments.
Because there are no FDA-approved therapies for PPMS, illness management usually entails a multidisciplinary approach. Medication to treat symptoms, physical therapy and rehabilitation, and assistive technologies to help patients preserve mobility and independence are all possibilities.
As more people are identified and novel therapies are produced, the market for PPMS treatments is projected to rise in the future years. However, the exorbitant expense of these therapies may prevent some patients from receiving them. Furthermore, further study is required to better understand the underlying processes of PPMS and to create more effective and cost-efficient therapies.
Global Primary Progressive Multiple Sclerosis Treatment Market to Amid COVID-19 Pandemic:
The COVID-19 pandemic has had a considerable influence on global healthcare systems, especially the treatment of multiple sclerosis (MS) and its different manifestations, including primary progressive multiple sclerosis (PPMS) (PPMS).
One of the most noticeable consequences of the epidemic has been a disruption in MS patient care, including delays in diagnosis, medication beginning, and routine monitoring. Many clinics and hospitals have decreased or eliminated in-person appointments, favouring telemedicine and remote monitoring. While this has allowed some people to continue getting care, it has also raised access and quality of care concerns. The pandemic has also had an impact on the development and approval of novel PPMS medicines. New medication clinical studies have been postponed.
The pandemic has also had an impact on the development and approval of novel PPMS medicines. Clinical studies for new pharmaceuticals have been delayed or cancelled, and regulatory bodies have struggled to assess and approve novel therapies on time. Furthermore, the pandemic’s economic impact has prompted worries regarding the pricing and accessibility of new medicines for PPMS and other disorders.
Despite these obstacles, there have been some encouraging advancements in the PPMS therapy industry in the midst of the epidemic. The rising use of telemedicine and remote monitoring has emphasised the potential for digital health technology to enhance MS patients’ access and quality of care. Furthermore, the quick development and licencing of COVID-19 vaccines has shown the potential for faster medication development and regulatory processes.
Overall, the COVID-19 pandemic has had a substantial influence on the PPMS treatment industry, presenting patients, healthcare professionals, and pharmaceutical businesses with both problems and possibilities. As the pandemic progresses, it will be critical to monitor its long-term consequences on the PPMS treatment industry and devise measures to limit its bad effects while capitalising on its good ones.
Emerging Markets for Primary Progressive Multiple Sclerosis Treatment Market:
The rising incidence of the condition in the region, as well as the development of innovative medicines and the use of digital health technology, are driving the emerging market for PPMS treatment in North America. In the United States, for example, it is believed that around 15% of all MS patients have PPMS, with 10,000 new cases identified each year.
In North America, numerous medicines are being developed for the treatment of PPMS, including siponimod and masitinib. Furthermore, the region is home to a number of world-class academic and scientific institutes that are performing cutting-edge research into the disease’s underlying causes and the development of novel therapies.
There is also rising interest in using digital health technologies like telemedicine and remote monitoring to increase access to care for PPMS patients in North America. These technologies have the ability to eliminate barriers to care, such as geographic distance and mobility limitations, while also improving patient outcomes.
Overall, the developing market for PPMS treatment in North America is likely to grow further, owing to a combination of rising illness incidence, breakthroughs in treatment choices, and increased usage of digital health technology.
The market for primary progressive multiple sclerosis (PPMS) therapy is extremely competitive, with numerous established and rising businesses vying for market dominance. Biogen, Novartis, Genzyme, Merck, Teva Pharmaceuticals, and Roche are among the market’s major participants.
Biogen, for example, is a market leader in the PPMS therapy industry, with multiple medications in development for the treatment of MS and associated diseases. Tysabri, one of its drugs, is licenced for the treatment of relapsing types of MS and is now being evaluated in clinical studies for the treatment of PPMS.
- Collaborations and alliances: Collaborations between corporations or organisations that share resources, information, and skills in order to achieve a common objective. These collaborations can assist firms in capitalising on one other’s strengths and accelerating the development and marketing of novel goods and cures. Biogen and Eisai partnered on the development and commercialization of Biogen’s Tysabri medicine for the treatment of MS, which is an example of collaboration and alliance in the PPMS treatment market.
- Product Launches and Innovations: The introduction of new items or technology into the market is referred to as a product launch or an invention. Product releases and advancements in the PPMS treatment industry can assist organisations in differentiating themselves from competition and capturing market share. Novartis’ Siponimod, for example, is a novel medicine that was recently licenced for the treatment of PPMS and has been found to be beneficial in reducing disease progression.
- Expansion: The expansion of a company’s activities into new markets or locations. Expansion in the PPMS treatment industry can assist organisations in reaching new patient groups and seizing new market possibilities. For example, Roche has announced intentions to expand its operations in Canada, allowing the business to access more PPMS patients in the nation.
- Acquisitions and Mergers: Acquisitions and mergers are business consolidations that occur when one firm buys or merges with another. Acquisitions and mergers in the PPMS treatment industry can assist firms in expanding their product portfolios and entering new markets. Biogen, for example, recently purchased Nightstar Therapeutics, a gene therapy business, in order to extend its ophthalmology footprint and research novel gene therapies for the treatment of retinal illnesses.
The PPMS treatment industry is very competitive in general, with multiple established and developing competitors fighting for market dominance. As the industry evolves and new cures are produced, organisations must stay nimble and responsive to changing patient requirements and market dynamics.